Simris Alg AB (publ) (SIMRIS-B) - Total Assets
Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) holds total assets worth Skr142.46 Million SEK (≈ $15.33 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Simris Alg AB (publ) to assess the company's total reinvestment commitment from operating cash flow.
Simris Alg AB (publ) - Total Assets Trend (2012–2025)
This chart illustrates how Simris Alg AB (publ)'s total assets have evolved over time, based on quarterly financial data. Check SIMRIS-B intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Simris Alg AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
Simris Alg AB (publ)'s total assets of Skr142.46 Million consist of 11.1% current assets and 88.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 1.0% |
| Accounts Receivable | Skr13.93 Million | 9.4% |
| Inventory | Skr1.08 Million | 0.7% |
| Property, Plant & Equipment | Skr11.36 Million | 7.7% |
| Intangible Assets | Skr120.55 Million | 81.3% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Simris Alg AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Simris Alg AB (publ) stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Simris Alg AB (publ)'s current assets represent 11.1% of total assets in 2025, a decrease from 89.3% in 2012.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2025, down from 71.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 81.3% of total assets.
Simris Alg AB (publ) Competitors by Total Assets
Key competitors of Simris Alg AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Simris Alg AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.99 | 0.20 | 2.14 |
| Quick Ratio | 0.90 | 0.17 | 0.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-118.00K | Skr-16.55 Million | Skr7.65 Million |
Simris Alg AB (publ) - Advanced Valuation Insights
This section examines the relationship between Simris Alg AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.31 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -5.5% |
| Total Assets | Skr148.38 Million |
| Market Capitalization | $13.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Simris Alg AB (publ)'s assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Simris Alg AB (publ)'s assets decreased by 5.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Simris Alg AB (publ) (2012–2025)
The table below shows the annual total assets of Simris Alg AB (publ) from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr148.38 Million ≈ $15.97 Million |
-5.52% |
| 2024-12-31 | Skr157.06 Million ≈ $16.90 Million |
-10.02% |
| 2023-12-31 | Skr174.55 Million ≈ $18.78 Million |
-6.01% |
| 2022-12-31 | Skr185.71 Million ≈ $19.99 Million |
+535.98% |
| 2021-12-31 | Skr29.20 Million ≈ $3.14 Million |
-48.83% |
| 2020-12-31 | Skr57.06 Million ≈ $6.14 Million |
+9.31% |
| 2019-12-31 | Skr52.21 Million ≈ $5.62 Million |
+4.76% |
| 2018-12-31 | Skr49.84 Million ≈ $5.36 Million |
-8.37% |
| 2017-12-31 | Skr54.39 Million ≈ $5.85 Million |
-28.77% |
| 2016-12-31 | Skr76.35 Million ≈ $8.22 Million |
+37.27% |
| 2015-12-31 | Skr55.62 Million ≈ $5.99 Million |
+412.10% |
| 2014-12-31 | Skr10.86 Million ≈ $1.17 Million |
+71.52% |
| 2013-12-31 | Skr6.33 Million ≈ $681.52K |
-5.68% |
| 2012-12-31 | Skr6.71 Million ≈ $722.54K |
-- |
About Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more